Schultz Quits After Novo Opts to Keep Rebien Sorensen as CEO

Updated on

Novo Nordisk A/S demoted President Kaare Schultz, 15 months after putting him in line to become the next chief executive officer, prompting him to walk out after 26 years at the world’s largest insulin maker.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.